AIDS Stages of Care – Three So Far; Will Number Four Come Soon? It All Depends on Finding A Vaccine

[Stephen C Schimpff]

It was just 30 years ago in June 1981 when the first cases of what came to be known as Acquired Immune Deficiency Syndrome (AIDS) were published by the Centers for Disease Control (CDC) in its Morbidity and Mortality Weekly Report (MMWR.) These were men who had a wasting illness and died of unusual infections, ones of the types seen mostly in “immunocompromised hosts.” These were infections with which I was very familiar in my work treating and preventing infections in aggressively treated cancer patients at a branch of the National Cancer Institute. They included pneumocystis, cyrptococcus, toxoplasma, candidia, zoster, disseminated herpes simplex and others. They tended to develop in patients who had a type of cancer that suppressed their cellular immune function as in chronic lymphocytic leukemia, lymphoma, Hodgkin’s or after bone marrow transplantation. Some of these same infections occurred in patients who received drugs to prevent rejection after kidney, heart or lung transplants. So it was immediately clear that what would become known as AIDS was a disease that markedly affected the cellular immune function of these patients.

 

It would be only a few years, 1984, until the causative agent was discovered to be a retrovirus (Dr Robert Gallo and Dr Luc Montaginer) and a test was developed (Gallo) to render the blood supply safe. Meanwhile the initial years of what soon was recognized to be an epidemic were spent treating these opportunistic infections in these patients with a rapidly fatal disease once it was diagnosed as AIDS. In retrospect this was the first stage or phase of disease management; it would evolve over the years.

 

By 1987 the first of the antiviral drugs zidovudine (or AZT) to actually treat the underlying HIV infection was approved by the FDA after studies began at Burroughs Welcome by David Barry, MD and others and at the National Cancer Institute by Samuel Broder, MD and others. Approval came within 25 months of initial studies; a record at the time. Soon came many other drugs and by 1996 there were multiple active agents which when combined produced HAART or Highly Active Anti Retroviral Therapy. This was a distinct turning point because for the first time this lethal disease became a controllable chronic illness where one could survive for decades or possibly more. But if one stopped the drugs once immune function returned toward normal, the disease rapidly recurred in force. So it was suppressed but definitely not cured. Now the key was to get the drugs to the patient, get good compliance and give careful follow-up. Getting the drugs to the patient is no mean feat since they are inherently expensive and many patients are uninsured or underinsured. Taking multiple drugs many times per day is difficult for anyone but harder still if the person is living in poverty or is homeless or is a child with perhaps drug addicted parents. And careful follow-up is difficult for all of the same reasons plus others. And of course the challenges are perhaps even more difficult in many developing countries where the stigma of AIDS is high and the logistical means of getting both the drug and the caregiver to the patient are immense, yet this is just where the vast majority of infected individuals live.

 

Now a third stage has evolved. With many patients living very long times, caregivers are witnessing a set of new challenges. These are the consequences of long term chronic illness and long term drug treatment. Many patients develop a unique change in body habitus with loss of fat in the face and limbs but an increase in abdominal adipose tissue deep in and around the viscera. The metabolic syndrome is frequent and it is followed by diabetes in many. And late onset cancers of many types are being increasingly recognized. Early onset coronary artery disease is another manifestation of the changing nature of this disease and its treatment. Some believe that the chronic infection leads to chronic inflammation which in turn drives the intimal development of plaque in the coronary arteries and others like the carotids. Early onset osteoporosis is also common with 50 to 67% having osteoporosis or osteopenia well before the expected age. With continued loss of bone mineral density, the risk of fracture at an earlier age with its attendant implications for loss of mobility, hospitalization and death is high.

 

So for the physician, the change in these evolving stages has been from spending 90% time managing infections to 90% managing the complexities of therapy, its many complications and the long term complications of the chronic infection. Today, the HIV patient on HAART needs regular evaluations for coronary artery disease, metabolic syndrome and osteopenia with life style adjustments and possibly further drug interventions as preventive measures.

 

There are over 25 licensed antivirals for HIV infection and more are on the way. But whichever ones are used, they must be continued. Stopping has repeatedly proven to be linked to relapse and earlier death.

 

What will the forth stage be and when will it begin? Let us hope it is the discovery of a vaccine. Only a vaccine will ultimately drive the epidemic down and possibly even contain or eradicate it the way smallpox was or polio and measles could be. The HIV has proven to be very difficult to conquer with a vaccine. Some of the problems include that the initial infection usually goes unnoticed and then it remains latent for many years until the earliest evidence of AIDS appears. Another is the ubiquity of the virus and its ability to undergo sufficient change to escape immune detection. Once the T cell is infected, it is infected for life so a vaccine must be used before, not after, exposure. Of course, there has never been a vaccine produced before to a retrovirus so this in itself is a new hurdle with limited knowledge from former vaccine research to base today’s work upon. The vaccine must block the virus’ ability to enter the cell suggesting an antibody rather than a cellular immune-based vaccine. Dr Robert Gallo, Director of the Institute of Human Virology - believes the target must be the virus envelope – the “fingers” that attach to the T lymphocyte. He and his colleagues recently received over $24 million from the Gates Foundation and the military to further research in this direction.

 

With about 2,700,000 new infections per year worldwide, a vaccine cannot come too soon.  But even when it does, the logistics of getting it to the world’s neediest will be fraught with difficulties. If getting susceptible children immunized against polio and measles has been difficult, HIV will be much more so.

[Roulette Wm. Smith, PhD]

I fully agree with Schimpff's viewpoint. Yet, it is somewhat lamentable that he and others overlook a somewhat counter-intuitive (nonetheless logical and obvious) approach to crafting vaccines against AIDS, though not HIV per se.

 

I first pointed out (Smith, 1984; also see Smith and Shadel, 2010) that vaccines against selected pathogens that would be "opportunistic" in HIV/AIDS effectively vaccinate against AIDS by circumventing the trans-activation of HIV. Then, by a process of attrition, titers of HIV will decline. This approach derives from the observation that opportunistic pathogens in HIV/AIDS generally are relatively uncommon. Stated differently, common pathogens (and vaccines against common pathogens) generally do not trans-activate HIV if persons are exposed to those pathogens prior to their exposure to HIV. Insofar as pathogens are region-specific, it is essential that epidemiologic profiles of common versus uncommon pathogens are established by public health agencies. [NB: This logic explains why there are regions of HIV-exposed persons that have different opportunistic pathogens (Smith, 2001).]

 

This negative approach to vaccines is problematic for pathogens that cis-activate HIV (e.g., herpesviruses; cf. Rosadio, 1983). Importantly, pathogens that cis-activate HIV do provide opportunities for understanding co-factors, co-infections and co-morbidities associated with HIV/AIDS. Indeed, my notions of autotoxicity, autovirulence and context-specificity (Smith, 1984) were derived from my observation of Epstein-Barr virus actions and byproducts in HIV-infected persons. Autovirulence now can explain why common viruses can cause relatively uncommon disorders and conditions (Fisher, 2009).

 

Negative vaccination approaches are instructive for other reasons. An understanding of lentivirus mechanisms and actions (and their broad implications for evolution) depends critically on understanding the underlying logic captured in the application and utility of two axioms from sentential logic (Modus Tollendo Tollens, in contrast to Modus Ponendo Ponens) in characterizing logics underlying HIV/AIDS (Smith, 1983; Smith and Shadel, 2010).

 

References

 

Fisher, C. (2009). A Novel and Potentially Groundbreaking Viral Theory of Autism and Schizophrenia. Behavioral Medicine Report (Available online at a href="http://www.bmedreport.com/archives/1411">http://www.bmedreport.com/archives/1411>; Thursday March 19th, 2009).

 

Rosadio, R. H. (1983). In vitro characterization of herpesviruses isolated from goats and sheep, Master's thesis; Washington State University, Pullman, Washington USA.

 

Smith, R. W. (1983). How Would You Recognize and Detect a Virally Modified Code? Could Kuru be Caused by Cannibalism of Autotoxic Factors in Brain and Lymphoid Tissue? Does Purification of Molecular Function Differ from Purification of Molecular Structure? *** A Critique of Impure Reasoning in Biological Sciences.  Abstracts, 7th International Congress of Logic, Methodology and Philosophy of Science [Salzburg, AUSTRIA — July] 4:358-362.

 

Smith, R. W. (1984). AIDS and 'Slow Viruses'. Annals of the New York Academy of Sciences 437:576-607. Based on a presentation to the Conference on Acquired Immune Deficiency Syndrome (AIDS), New York Academy of Sciences [New York, NY — November, 1983]

 

Smith, R. Wm. (2001). Opinion: The Durban Declaration. The Scientist 15(2):39. [Also available at:  http://www.the-scientist.com/yr2001/jan/opin_010122.html].

 

Smith, R. W. and Shadel, R. R. (2010). Preliophic Moleculator Using Electric Fields and Gradients for Manipulating Molecules. US Patent #7,826,974 B2 (November 2, 2010; also see a href="http://%3C/body">